What is the SymGene Focus – Melanoma Cancer Panel?
The melanoma cancer panel is a validated genomic profile that includes 7 genes with compelling clinical and biological evidence as biomarkers to predict drug responses. The genes in our panel are connected with approved drugs in standard care or for off-label drugs in clinical trials.
Who Should Have This Test Run?
Genetic profiling of these genes is useful for identifying targets amenable to targeted therapies, such as BRAF inhibitors, MEK inhibitors, or combination of them, and predictable for response or resistance to specific targeted therapies. SymGene Melanoma can also be used to help determine clinical trial eligibility for patients with alterations in genes not amenable to current FDA-approved targeted therapies.
Test Details
• Designed for tumor profiling of primary or metastatic melanoma cancer.
• Assesses all coding exons of each gene for substitutions, insertions and deletions of less than 50 bp, and copy number variants (gene amplifications or homozygous loss).
• This test is intended to evaluate for somatic mutations within tumor samples; is unable to differentiate the somatic or germline origin for the detected variants.
What Genes Are Included in the Melanoma Cancer Panel?
BRAF NRAS KIT CTNNB1 GNAQ GNA11 GNAS
Order SymGene
Healthcare providers with several options for ordering SymGene for their patients including LabDOX, fax, and phone. Healthcare providers must first complete a test requisition form to start the process. Turn around time is 7-10 days from the time a specimen is received.
